06 Jul 2022

London, 06, July 2022, BenevolentAI (“BenevolentAI” or the "Company") ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, today announces that Dr Nicola Richmond has joined BenevolentAI as Vice President of Artificial Intelligence. She will be responsible for spearheading the Company’s AI strategy and working to ensure BenevolentAI maintains its leading position in AI-enabled drug discovery. 

Nicola joins BenevolentAI’s product and technology leadership team, reporting to Chief Technology Officer Dr Daniel Neil. She brings a wealth of experience in developing innovative ways of leveraging data to advance drug discovery and development. Previously, she spent 18 years at GSK, where she held a number of leadership roles and was responsible for developing methodologies for maximising the value of high-throughput, high-content screening data, leading early small molecule drug discovery programmes and building the GSK.ai Fellowship Programme.

Daniel Neil, CTO said: “We are thrilled to welcome Nicola to the BenevolentAI team. Nicola brings with her a rare combination of leadership, technical and strategy skills that cut across AI and drug discovery. She will be pivotal in enabling the Company to explore new frontiers for where we can apply AI to early-stage drug discovery and helping to consolidate BenevolentAI’s position at the forefront of this rapidly evolving field.”

Dr Nicola Richmond, VP of AI said: "I am fascinated by how data and AI can help empower scientists to understand human biology in previously unimaginable ways, and believe we have only just seen the beginning of how these new technologies can transform conventional drug discovery and development. I look forward to working with BenevolentAI’s world-class team to take the Company’s technology to the next level and realise their mission of uniting human and machine intelligence to discover life-changing drugs".

Prior to working at GSK, Nicola worked in chemoinformatics in the Statistics and Modelling Group at Unilever R&D, and later completed a postdoc with Prof. Peter Willett at the University of Sheffield, where she worked on developing novel techniques for a range of important chemoinformatics applications. Nicola has a BSc in Mathematics, an MSc in Computer Science from the University of Edinburgh, and a PhD in Pure Mathematics from the University of Leeds. 

About BenevolentAI

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 disease programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI also identified Eli Lilly's baricitinib as a repurposing drug candidate for COVID-19, which has been authorised for emergency use by the FDA. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Fleur Wood - VP Investor Relations


Rajin Kang - VP Communications


Back to press releases and in the media